Alberto Sepulveda

Associate, Strategy & Analytics

Alberto joined Royalty Pharma in 2021. Previously, Alberto spent a year as an equity research associate at Cantor Fitzgerald focusing on smid-cap biotechnology companies in rare disease, inflammation/immunity, and innovative therapeutic spaces. There, he helped Ellie Merle launch her coverage, and worked ad-hoc on projects for Alethia Young. Since leaving Cantor in late 2020, Alberto has been helping the team at ProKidney progress to a Phase III trial.

Alberto came to the US in 2010 to study at the University of Rochester. He was first introduced to Royalty Pharma in the summer of 2012, when he served as an intern with the Research team. After graduating with a BS in Neuroscience, Alberto joined Georgetown University's Interdisciplinary Program in Neuroscience for his PhD (completed 2019), where he trained as an electrophysiologist, pharmacologist, and neuroimmunologist.